China Sickle Cell disease treatment Market: Segmented by Treatment modality (Blood transfusion, Bone marrow transplant and Pharmacotherapy), End users (Hospital, Speciality clinics and Others) - Growth, Trends, and Forecasts (2019 2028)
- Published Date: 2022-12-28
- Report ID: 139822
- Pages: 200
-
Format:
Report Overview
The China Sickle cell disease treatment market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of 4.9% during the forecast period.
The impact of COVID-19 on chinese geography was huge and due to which sickle cell disease witnessed a positive demand from this geography. The chinese government is focusing on fast-track approval and research grants to encourage pharmaceutical companies in developing novel therapies for the disease. The accelerated research coupled with pipeline projects is expected to propel the sickle cell market in china.
Market Drivers
Increasing prevalence of sickle cell disease is the main driver of this market. The incidence of sickle cell disease is approximately 0.68% in the chinese population. Another factor is the introduction of new therapies and products which is favoring the market expansion for the future. The government policies to infuse grants and expand the research base for the disease is attracting the major MNCs across the globe towards multiple sclerosis market in china. High cost of treatment is restraining the market growth but can be tackled with proper insurance policies.
1. China Sickle cell disease treatment Market Overview...................................
A. Market Size
2. Market Growth Drivers.......................................................................................
A. Increasing prevalence of Sickle cell disease and introduction of new therapies
B. Government initiatives and expansion of the research base
3. Types of Sickle cell disease................................................................................
A. Sickle cell Anaemia
B. Sickle Haemoglobin-C
C. Sickle Beta-Plus Thalassemia
D. Sickle Beta-Zero Thalassemia.
4. Sickle cell disease treatment Market Segmentation.....................................
A. Treatment Modality
I. Blood transfusion
II. Bone marrow transplant
III. Pharmacotherapy
B. End users
I. Hospitals
II. Speciality clinics
III. Others
5. Sickle cell disease treatment Major Products Market Share........................
A. Key Findings
B. Market Analysis, Insights and Forecast
6. Competitive Landscape........................................................................................
A. Major Players
B. Products in Pipeline
7. Key Company Profiles...........................................................................................
A. Pfizer Inc. Company overview, Product & Services, Strategies & Financials
B. Gamida cell Company overview, Product & Services, Strategies & Financials
C. Modus therapeutics Company overview, Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape..............................................
A. Policy changes and Reimbursement scenario
9. Factors Driving Future Growth..........................................................................
A. New Trends and Development of Sickle cell disease treatment market
B. Future Opportunities
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
